skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Three-compartment modeling of C-11 N-Methyl spiperone kinetics in the human brain

Conference · · J. Nucl. Med.; (United States)
OSTI ID:6929159

N-Methyl spiperone, as well as spiperone, has been used to study the dopamine receptor system in the brain. The authors have applied a 3-compartment model consisting of vascular, extravascular unbound, and receptor-bound activity to two normal volunteers and one patient with Parkinson's disease. The model differs from that proposed by another study, in that, as in the Sokoloff model for deoxyglucose, there is no explicit term for blood flow. Furthermore, the authors used a 3-compartment model for the cerebellum as well as the caudate/putamen. Serial scans were obtained by PET for up to 2 hrs after injection of the tracer. Time-activity curves were generated over the caudate, putamen and cerebellum. The results indicate a close fit of the observed data to the 3-compatment model. In the model, K1 represents the rate constant of delivery of the tracer in the tissue from the vascular compartment. K2 is the reverse rate constant. K1 was approximately equal to K2 for the cerebellum. In the basal ganglia, K2 was less than K1 due to nonspecific binding in compartment 2. K3 represents the rate constant of binding of the tracer to the receptor binding sites in the cerebral cortex and basal ganglia and to nonspecific binding sites in the cerebellum which contains essentially no dopamine receptors. K4 represents the rate constant for dissociation of the tracer from the receptors. For N-methyl spiperone K4 is very low in the caudate/putamen. The 3-compartment model seemed to fit the data better than the 2-compartment model for both the caudate/putamen and cerebellar activity.

Research Organization:
National Institutes of Health, Bethesda, MD
OSTI ID:
6929159
Report Number(s):
CONF-840619-; TRN: 87-008948
Journal Information:
J. Nucl. Med.; (United States), Vol. 25:5; Conference: 31. annual meeting of the Society of Nuclear Medicine, Los Angeles, CA, USA, 5 Jun 1984
Country of Publication:
United States
Language:
English